Digital therapeutics for CBT find a real tier
FDA-cleared digital therapeutics for cognitive behavioural therapy are moving past pilots into routine prescribing pathways.
Digital therapeutics for cognitive behavioural therapy have struggled commercially despite strong clinical evidence. The 2024-2026 cycle of payer coverage decisions has shifted the picture. Several FDA-cleared products now have meaningful commercial coverage, and the prescribing pathway through primary care and psychiatry is finally taking shape. The category is no longer pre-revenue.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.